Glow-in-the-Dark dye could help breast cancer patients avoid second surgery
NCT ID NCT07140965
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a special fluorescent dye and imaging system can help surgeons see and remove all cancer during breast-conserving surgery. The goal is to reduce the chance that cancer cells are left behind, which often requires a second operation. About 175 women with breast cancer will take part. The trial is currently on hold.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pegulicianine (fluorescent dye) used with the Lumicell Direct Visualization System
What this could lead to
If successful, this approach could help surgeons remove all cancer in one operation, reducing the need for a second surgery and improving outcomes for breast cancer patients.
What could go wrong
This trial is currently suspended, and it is a relatively small, early-stage study focused on safety and feasibility. The technology may not work as hoped or may not reduce second surgeries significantly.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States